According to a new article, to be published on line today in The Lancet, abiraterone acetate + prednisone provides a median overall survival benefit of 4.6 months compared to a placebo in men with metastatic, castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: abiraterone survival, castrate-resistant, mCRPC, metastatic | 15 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 